Physician profile
Thomas J Kasper
NPI 1366418238
$3,169.10
in general payments reported to CMS, 2019-2025
25 companies · $439 in 2025
The $439 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $189 · 2021: $362 · 2022: $696 · 2023: $751 · 2024: $517 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $665.32 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $436.89 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Cranial Technologies, INC | $345.45 | 2021-2025 | Doc Band |
| Ironshore Pharmaceuticals INC. | $310.88 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $242.91 | 2019-2025 | Bexsero, Flulaval Quadrivalent |
| Corium, LLC | $236.89 | 2021-2023 | Azstarys |
| Pfizer INC. | $214.47 | 2021-2025 | |
| Sobi, INC | $111.51 | 2019-2023 | |
| Adlon Therapeutics L.P. | $91.75 | 2020-2021 | |
| Sanofi Pasteur INC. | $72.68 | 2019-2024 | |
| Abbvie INC. | $56.03 | 2025 | |
| Collegium Pharmaceutical, INC. | $55.21 | 2025 | Jornay Pm |
| Kyowa Kirin, INC. | $48.34 | 2024 | Crysvita |
| Nestle Healthcare Nutrition INC. | $35.13 | 2023 | |
| Sanofi-Aventis U.S. LLC | $33.15 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.12 | 2024-2025 | Gardasil 9, Vaxelis, Rotateq |
| Seqirus USA INC | $29.72 | 2025 | Flucelvax |
| Vertical Pharmaceuticals, LLC | $28.85 | 2019 | |
| Aquestive Therapeutics, INC. | $22.56 | 2019 | |
| Ironwood Pharmaceuticals, INC | $21.16 | 2024 | |
| Phadia US INC. | $20.17 | 2024 | Immunocap |
| Mission Pharmacal Company | $17.48 | 2019 | |
| Neurelis, INC. | $15.45 | 2024 | Valtoco |
| Kowa Pharmaceuticals America, INC. | $13.62 | 2025 | Zoryve |
| Ultragenyx Pharmaceutical INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.